With the continuous expansion of the biopharmaceutical market, the domestic substitution of biopharmaceutical equipment will accelerate

[Pharmaceutical Network Market Analysis] The biopharmaceutical industry is an important industry related to the national economy and people's livelihood, and is closely related to the needs of people's healthy life and the protection of national health and safety
.

Since the beginning of this year, many places have accelerated the pace of development of the biopharmaceutical industry and issued relevant documents to help
.

 The biopharmaceutical market continues to expand, and the domestic substitution of biopharmaceutical equipment is accelerating (Photo source: Pharmaceutical Network) Various regions are vigorously developing the biopharmaceutical industry , the province's bio-pharmaceutical industry operating income to achieve the goal of "protecting four and competing for five"
.

According to the target, by 2025, the operating income of the biopharmaceutical industry in Yunnan Province will also be guaranteed to reach 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth rate of more than 10%
.

Among them, the biopharmaceutical manufacturing industry achieved operating income of more than 150 billion yuan, with an average annual growth rate of more than 20%; the added value of the biopharmaceutical industry reached 120 billion yuan, with an average annual growth rate of more than 10%
.

Not long ago, Chongqing also issued "Several Measures to Accelerate the Development of Biomedical Industry in Chongqing" (hereinafter referred to as "Measures")
.

It is clearly stated that from the aspects of cash reward, professional title review, internal performance distribution, etc.
, it will be inclined to medical and public health staff and front-line staff of clinical research who have made important contributions to the completion and transformation of the scientific and technological achievements, and establish clinical research incentives.
mechanism
.

Among them, in terms of new drugs, Chongqing has also listed a list of incentives for this
.

For innovative drugs, improved new drugs and biosimilar drugs (all of the above include biological products, the same below), project support will be established in accordance with the four stages of preclinical research, phase I clinical trials, phase II clinical trials, and phase III clinical trials.
Financial support of no more than 20% of the R&D investment, with the highest intensity of financial support being 3 million yuan/item, 2 million yuan/item, 3 million yuan/item, and 7 million yuan/item
.

 　　In addition to the above provinces and cities, since this year, Shanghai, Hefei, Chongqing and other places have also issued documents to vigorously develop the biopharmaceutical industry, and proposed to move towards the "100 billion level" market in the next few years
.

In this regard, the industry believes that under the background of accelerating the development of the biopharmaceutical industry in various places, China's biopharmaceutical industry will continue to move in the direction of high quality, and the market will continue to expand
.

Some forecasts show that the scale of China's biological drug market will increase from 152.
7 billion yuan in 2016, maintain a compound annual growth rate of 16.
4%, and exceed 400 billion yuan by 2022
.

 　　The biopharmaceutical market continues to expand, and the importance of pharmaceutical equipment will increase.
Under the background of favorable policies for the domestic biopharmaceutical industry, the vigorous development of the biopharmaceutical industry, and the continuous expansion of the market, analysts believe that the development of China's pharmaceutical equipment industry is also expected to enter a new stage.
growth stage
.

 　　Biopharmaceutical equipment belongs to the upstream of the biopharmaceutical industry, including a series of equipment such as bioreactors, chromatography columns, filters, and light inspection machines
.

According to data, in 2020, the global biopharmaceutical equipment and consumables market will reach approximately US$18.
7 billion.
Frost & Sullivan expects that the global equipment and consumables market will maintain a growth rate of 8%-10% in the next five years
.

In this context, China's biopharmaceutical equipment and consumables market, as a rapidly developing and potential market, will have very broad prospects in the future
.

 　　At present, many pharmaceutical equipment companies have accelerated their deployment in this field
.

Rutofflon has launched a fixed increase fund-raising action since its listing some time ago.
The company plans to raise no more than 3.
2 billion yuan to expand production capacity to meet the rapidly growing downstream market demand
.

It is reported that the funds raised will be used for the construction of the biopharmaceutical equipment industry trial production center, Jiangsu biomedical equipment industrialization base, Hangzhou life science industrialization base and other projects.

.

 　　In recent years, Chutian Technology has also made rapid progress in the front-end process and equipment layout of biopharmaceuticals.
Since 2021, Chutian Usite and Chutian Microspheres have been established successively, which are respectively used for related single-use process equipment in the field of biopharmaceuticals.
, production and sales of consumables and software, as well as the development and production of biopharmaceutical process products such as disposable bioreactors, liquid dispensing bags, liquid storage bags and their membrane materials
.

At the end of February this year, Chutian Technology announced the establishment of a holding company, Chutiansiweikang Gene, which is committed to promoting the layout in the field of biotechnology
.

 　　Conclusion The industry expects that in the context of the accelerated development of the biopharmaceutical industry, the pace of domestic substitution of biopharmaceutical equipment is expected to accelerate in the future
.

With the development of China's pharmaceutical equipment technology and the continuous increase in R&D investment of pharmaceutical machine companies, some biological pharmaceutical equipment will also accelerate the pace of replacing imports
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.